ArticleWorld journal of urology2026
Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe UroVysion assay is widely used for diagnosing upper tract urothelial carcinoma (UTUC), but its value in patients with negative urinary cytology remains unclear. This study evaluated its diagnostic performance and pathological associations in this specific population.
methodsThis retrospective study included 1,256 patients with upper tract lesions on imaging, negative urinary cytology, and preoperative UroVysion testing. Pathological diagnosis served as the reference standard. Diagnostic performance was assessed using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy. Logistic regression analysis was used to evaluate the association between UroVysion positivity and high-grade disease, lymphovascular invasion (LVI), and muscle invasion (≥ pT2). Subgroup analyses were performed according to tumor size and location.
resultsAmong the 1,256 patients, 1,007 (80.2%) had UTUC and 249 (19.8%) had benign lesions. The UroVysion assay showed a sensitivity of 66.9%, specificity of 82.7%, PPV of 94.0%, and NPV of 38.2%, and an overall accuracy of 70.1% for UTUC diagnosis. UroVysion positivity was independently associated with high-grade disease (OR = 2.10, p < 0.001), LVI (OR = 1.63, p = 0.023), and muscle invasion (OR = 1.32, p = 0.049). Interaction tests showed no significant heterogeneity by tumor size or tumor location.
conclusionIn patients with upper tract lesions and negative cytology, the UroVysion assay provides complementary diagnostic information and is associated with adverse pathological features. No significant heterogeneity in these associations was observed according to tumor size or location.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.